Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
about
Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophreniaGroup II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt/GSK-3β pathway in adult rat prefrontal cortexDiscovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM)Norbin is an endogenous regulator of metabotropic glutamate receptor 5 signalingGroup II Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic DrugsNegative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic WindowRecent progress in understanding subtype specific regulation of NMDA receptors by G Protein Coupled Receptors (GPCRs)Emerging approaches for treatment of schizophrenia: modulation of glutamatergic signalingThe Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys.Perspective-taking abilities in the balance between autism tendencies and psychosis pronenessMetabotropic glutamate receptor-mediated signaling in neurogliamGlu2 Receptor Agonism, but Not Positive Allosteric Modulation, Elicits Rapid Tolerance towards Their Primary Efficacy on Sleep Measures in RatsAllosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's diseasePerspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.Design and synthesis of systemically active metabotropic glutamate subtype-2 and -3 (mGlu2/3) receptor positive allosteric modulators (PAMs): pharmacological characterization and assessment in a rat model of cocaine dependence.Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinAllosteric modulation of metabotropic glutamate receptors.Advancing drug discovery for schizophrenia.Metabotropic glutamate receptors: from the workbench to the bedside.mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotionTargeting glutamate synapses in schizophreniaGroup II mGluR agonist LY354740 and NAAG peptidase inhibitor effects on prepulse inhibition in PCP and D-amphetamine models of schizophrenia.Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and in vivo activity in rat behavioral models of anxiolytic and antipsychotic activity.Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Discovery of a Novel Chemical Class of mGlu(5) Allosteric Ligands with Distinct Modes of Pharmacology.Structure-activity relationships comparing N-(6-methylpyridin-yl)-substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonistIdentification of Metabotropic Glutamate Receptor Subtype 5 Potentiators Using Virtual High-Throughput Screening.Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity.LY395756, an mGluR2 agonist and mGluR3 antagonist, enhances NMDA receptor expression and function in the normal adult rat prefrontal cortex, but fails to improve working memory and reverse MK801-induced working memory impairment.Critical design issues in the targeted molecular imaging of cell surface receptors.Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.Targeting metabotropic glutamate receptors for novel treatments of schizophrenia.Theranostic Biomarkers for SchizophreniaStructure and ligand recognition of class C GPCRsSeven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅).mGluR5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learningCognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.Novel therapeutic drugs for neuropsychiatric disorders
P2860
Q22248085-9EEE195B-9D3D-4D7A-A162-8B96DC706FCFQ24612550-388F03F7-5C9C-488C-8E5F-96CB97E520C7Q24625985-7A17EE66-B916-4925-874A-204FDA4B04A6Q24655546-69254C7C-3A97-41D8-9609-B1ECF6FF8E8FQ26744729-052E9A25-946C-49E5-8469-8960BF262998Q26775243-9508BC70-0E9F-4AC8-A530-85036FA52C2FQ27006067-D07B36E0-A4D7-43C6-BAB3-9D04C57F90B9Q27023967-36FCA122-F327-4784-B60B-A5E2DCBCB404Q27325802-2CC798C9-E862-4DD6-BD0A-835DCABFF00BQ27330208-DD420836-178A-4FC7-AFFC-41A8FCD48CA5Q28385047-CA2A533F-64F0-4521-9967-B6E2A99AF10EQ28551598-305F4165-DD91-497D-9E6F-DBACA87027BDQ28660933-287BEA71-0038-4934-866B-5753DA3DCD96Q30379983-8A1F2604-FC39-410B-9DEE-26043CA311B9Q30387014-619FA457-C156-4B15-85FC-705040A1DFCDQ30414307-9D9BB547-651B-4001-AADF-CF05683DC9D9Q30427775-417C48F5-DB3A-45E0-BC71-31164E36348BQ30448534-AB65EFFD-2B37-4B71-9AEA-1926D86C6E10Q30448547-B9E717C2-0A09-4B04-8A1C-D6F7C5F5D89BQ30448778-E8AD20B8-A3AF-47CD-8CD0-B1F18F606599Q30450936-C44021C6-63C7-4925-B4C8-045A86428280Q30460392-F41E95A3-D471-414C-8797-3E70082E19D4Q30466262-E3B33BA8-DF36-49A2-A04C-65B75AFFD8D0Q30472643-7311017F-D595-40DB-990E-5B48DE112F8FQ30473410-03D84A3F-695E-4561-8B6C-DFAD384FB546Q30479035-C49D98CE-CF4C-4E56-A0D5-DBFA84D8E1F9Q30480859-202D1562-14A0-4F11-A255-0F608EA8BD47Q30481884-8B5506F2-1E7A-4B28-ADC7-B7B7E487A158Q30535764-82AFD7DB-37E2-4980-BAEA-548F4954F825Q30747587-2E28C4F7-1788-4C04-8FB2-308C582A71B4Q30899036-B4C554D8-6FB8-49B7-8F16-E41929D4B5C3Q33518105-459A6356-3873-46AA-BF9E-6385A4C7D123Q33604654-F0336B0F-6320-437A-B499-C21232E7D80AQ33624412-B6E960A2-187D-44DF-AE8F-3ED0DA66DFBEQ33828724-12AEA991-B66B-4E77-BDED-E94D6D379645Q33890786-158508FD-950A-4161-A161-037DFA5F4B23Q33894613-49E95221-1840-4CC1-A6BC-C6B9C6ACFDFBQ33908562-C78A0911-B2CC-4F2F-9CFC-46C08C4E0D0BQ33936309-5F587071-A666-48CF-B390-FCDAA5896294Q34018299-DCDC4298-8E82-4B77-B618-3214334AF032
P2860
Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 December 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Activation of metabotropic glu ...... he treatment of schizophrenia.
@en
Activation of metabotropic glu ...... he treatment of schizophrenia.
@nl
type
label
Activation of metabotropic glu ...... he treatment of schizophrenia.
@en
Activation of metabotropic glu ...... he treatment of schizophrenia.
@nl
prefLabel
Activation of metabotropic glu ...... he treatment of schizophrenia.
@en
Activation of metabotropic glu ...... he treatment of schizophrenia.
@nl
P2860
P1476
Activation of metabotropic glu ...... he treatment of schizophrenia.
@en
P2093
Carrie K Jones
P2860
P356
10.1016/J.TIPS.2008.10.006
P577
2008-12-06T00:00:00Z